This brand name is authorized in Brazil, South Africa
The drug PASURTA contains one active pharmaceutical ingredient (API):
|
1
Erenumab
UNII I5I8VB78VT - ERENUMAB
|
|
Erenumab is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor. CGRP is a neuropeptide that modulates nociceptive signalling and a vasodilator that has been associated with migraine pathophysiology. Inhibition of the effects of CGRP could theoretically attenuate compensatory vasodilation in ischaemic-related conditions. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N02CD01 | N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CD Calcitonin gene-related peptide (CGRP) antagonists | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 526519080094902, 526521030098402 |
| Country: ZA | Health Products Regulatory Authority | Identifier(s): 54/7.3/0587, 54/7.3/0588 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
